Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of “Moderate Buy” from Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received an average rating of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $43.33.

A number of equities research analysts have recently weighed in on ARWR shares. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, December 20th.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $18.49 on Friday. The company has a market capitalization of $2.30 billion, a PE ratio of -3.68 and a beta of 0.97. The company has a debt-to-equity ratio of 2.06, a quick ratio of 6.74 and a current ratio of 6.74. The company has a 50-day simple moving average of $21.05 and a two-hundred day simple moving average of $22.53. Arrowhead Pharmaceuticals has a one year low of $17.05 and a one year high of $39.54.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $21.90, for a total transaction of $82,081.20. Following the sale, the director now owns 44,125 shares of the company’s stock, valued at $966,337.50. This trade represents a 7.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher Richard Anzalone sold 26,712 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total transaction of $567,362.88. Following the sale, the chief executive officer now directly owns 3,688,335 shares in the company, valued at $78,340,235.40. The trade was a 0.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 146,473 shares of company stock worth $2,937,847 over the last quarter. Insiders own 4.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ARWR. Values First Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $52,000. Meeder Asset Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 4,629.2% during the 2nd quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 3,333 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $149,000. Finally, Quarry LP lifted its holdings in Arrowhead Pharmaceuticals by 54.5% in the 2nd quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 3,000 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.